ArticleSupportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer2026
Differences in perceptions of hematologists and palliative care physicians regarding transfusion therapy in patients with terminal hematological malignancies: a nationwide cross-sectional questionnaire survey in Japan.
Article in Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Blood Transfusion in End-of-Life Cancer Care: Clinical Evidence, Patient Blood Management and Goal-Concordant Practice.Medical sciences (Basel, Switzerland) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
purposeTo examine differences in perceptions between hematologists (HOs) and palliative care physicians (PCs) regarding red blood cell transfusion at the end of life.
methodsThis cross-sectional questionnaire survey, conducted from August to September 2020, included responses from 1000 hematologists (HOs) and 759 palliative care physicians (PCs). The questionnaire assessed cutoff indications and opinions regarding red blood cell transfusion for anemia due to hematologic malignancy progression in patients with no indication for anticancer therapy. We defined a consensus Hb threshold as the highest level at which ≥ 70% of respondents would transfuse.
resultsOf 659 responses, 596 were valid (269 HOs and 327 PCs). For symptomatic cases, > 70% of HOs and PCs considered Hb cutoffs of 8.0 and 7.0 g/dL, respectively. For asymptomatic cases, < 70% of PCs recommended transfusion even at Hb ≤ 6.0 g/dL; therefore, an Hb cutoff for PCs could not be determined. Most HOs and PCs agreed to reduce transfusion frequency, while PCs were more likely than HOs to agree to discontinue transfusion. In contrast, HOs were more likely than PCs to agree to continue transfusion upon patient and/or family request and to consider patients with performance status 4 eligible for transfusion.
conclusionAmong adult patients with hematological malignancies who have no indication for anticancer therapy, hematologists tend to view transfusion more favorably and to transfuse more actively than palliative care physicians. Greater mutual understanding and consensus-building regarding transfusion indications at the end of life may facilitate appropriate palliative care referral for these patients.
Indexed as
Identifiers
42287319What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.